26-Aug-2010

Saltigo GmbH will be raising its prices for the product group 1,2,4 Triazol (CAS 00288-88-0) by 10 % effective September 1, 2010. The reasons for the measure are substantial increases in raw materials and energy costs.

more

28-Jun-2010

Saltigo GmbH has passed an audit by the U.S. Food and Drug Administration (FDA) with a “No Findings” rating. Saltigo’s Managing Director Wolfgang Schmitz is delighted that the official auditors did not have any objections: “The FDA audit is an internationally accredited seal of quality and ...

more

Syngenta invests around EUR 50 million in Saltigo facilities

06-May-2010

Saltigo, a wholly owned subsidiary of LANXESS, is significantly expanding production at its Leverkusen site. This is being made possible by a cooperation agreement that is so far unique for the Group. Syngenta is investing some EUR 50 million in expanding several Saltigo facilities in Leverkusen ...

more

LANXESS subsidiary wins “Agrow Award 2009”

17-Nov-2009

Saltigo GmbH, a wholly owned subsidiary of LANXESS, has been rated as “Best Supplier” by the “Agrow” trade journal for the second time in succession and won against a strong competition from India, China and Europe. A panel of judges comprising eleven internationally recognized experts from the ...

more

02-Jul-2009

Saltigo GmbH targets Japanese custom manufacturing market, presenting its portfolio of services at Interphex/Pharma-i Japan Exhibition in Tokyo. Saltigo’s CEO Wolfgang Schmitz emphasizes: “This is Asia’s largest pharmaceutical industry event and has an excellent reputation for attracting key ...

more

Capacity increase and process optimization possible without interrupting production or limiting supply volumes

05-Jun-2009

Saltigo GmbH has succeeded in more than doubling capacity for five intermediates and two active ingredients for several agrochemical companies without needing to halt or interrupt the production process in any way. For three of these projects, higher volumes were achieved by implementing process ...

more

Capacity for active ingredient precursor nearly doubled

02-Feb-2009

Saltigo GmbH has demonstrated its wide-ranging expertise in the fields of synthesis optimization and process development. The global specialist for exclusive custom synthesis has succeeded in increasing capacity for an active ingredient precursor for a major pharmaceutical manufacturer without ...

more

13-Mar-2007

LANXESS is extending its activities in the area of insect repellents. LANXESS subsidiary Saltigo and the Italian company Endura SpA Fine Chemicals have signed a contract under whose terms Endura will market Saltigo's active ingredient Bayrepel® (Icaridin) with immediate effect in Central and ...

more

EUR 30 million investment to modernize the production base / EUR 10 million to build a high-tech multi-purpose plant

18-Jan-2007

LANXESS plans to develop the business of its fine chemicals subsidiary Saltigo. EUR 30 million has been earmarked for plant modernization, and new worktime models are to be introduced. A state-of-the-art multi-purpose facility costing a further EUR 10 million is already under construction. "The ...

more

09-Jun-2006

Die Saltigo GmbH und die Ilypsa, Inc. gaben die Bildung einer Kooperation zur Prozessentwicklung und Herstellung polymerer Pharmazeutika sowie Bereitstellung von Substanzmengen für die klinische Prüfung bekannt. Diese Geschäftsbeziehung umfasst zunächst Prozessentwicklung und Herstellung von ...

more